Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease

BMJ Open

Volumn 5, Issue 9, 2015, Pages

  Wood, Frances ^a   Salam, Abdul ^b,c   Singh, Kavita ^d,e   Day, Sophie ^f   Jan, Stephen ^c   Prabhakaran, Dorairaj ^d   Rodgers, Anthony ^c   Patel, Anushka ^b,c   Thom, Simon ^a   Ward, Helen ^f  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOLOGIST; CARDIOVASCULAR DISEASE; DIETARY INTAKE; ENDOCRINOLOGIST; EUROPE; EXERCISE; FATIGUE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; INDIA; MEDICATION COMPLIANCE; NEUROLOGIST; NURSE; PATIENT CARE; PATIENT COMPLIANCE; PHARMACIST; PHYSICIAN; POLYPHARMACY; PRESCRIPTION; PROPHYLAXIS; QUALITATIVE ANALYSIS; SMOKING CESSATION; TRAVEL; UNITED KINGDOM; AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR AGENT; DRUG COMBINATION;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; HUMANS; INCIDENCE; INDIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY PREVENTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84970937465     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008018     Document Type: Article

References (17)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
2. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011;378:1231-43.
3. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial. JAMA 2013;310:918-29.
4. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015;22:920-30. http://www.ncbi.nlm.nih.gov/pubmed/24676715 (accessed 16 Oct 2014).
5. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: Randomised controlled trial in primary care. BMJ 2014;348:g3318.
6. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: Results from the FOCUS project. J Am Coll Cardiol 2014;64:2071-82.
7. Webster R, Patel A, Billot L, et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. Int J Cardiol 2013;170:30-5.
8. Huffman D. Fixed dose combinations of cardiovascular drugs. BMJ 2014;348:g3480. http://www.bmj.com/content/348/bmj.g3480 (accessed 28 Oct 2014).
9. Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE): Rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2014;21:252-61.
10. Oakley A, Strange V, Bonell C, et al. Process evaluation in randomised controlled trials of complex interventions. BMJ 2006; 332:413-16.
11. Salam A, Stewart F, Singh K, et al. INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications. BMJ Open 2013;28:pii: E002313. http://www.ncbi.nlm.nih.gov/pubmed/23793693 (accessed 16 Oct 2014).
12. Glaser B, Anselm L. The discovery of grounded theory: strategies for qualitative research. Chicago: Aldine Publishing Company, 1967.
13. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: A review of systematic reviews. Front Pharmacol 2013;25:91. http://www.ncbi.nlm.nih.gov/pubmed/23898295 (accessed 16 Oct 2014).
14. Stone V. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001;33:865-72.
15. Mahtani KR, Heneghan CJ, Glasziou P, et al. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev 2011;(9):CD005025. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005025.pub3/abstract (accessed 16 Oct 2014).
16. World Health Organisation (WHO). Global burden of disease 2004 data. Geneva: provided by Colin Mathers, 2009.
17. Mayo E. Hawthorne and the Western Electric Company. In: Mayo E, ed. The social problems of an industrialized civilization. London: Routledge, 1949:60-76.